Sol-Gel Technologies PE Ratio 2016-2024 | SLGL

Current and historical p/e ratio for Sol-Gel Technologies (SLGL) from 2016 to 2024. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Sol-Gel Technologies PE ratio as of November 20, 2024 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Sol-Gel Technologies PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2024-11-19 0.43 0.00
2024-06-30 0.89 $-0.54 0.00
2024-03-31 0.98 $-0.83 0.00
2023-12-31 1.11 $-1.01 0.00
2023-09-30 1.63 $-1.09 0.00
2023-06-30 2.99 $-1.03 0.00
2023-03-31 3.88 $-0.82 0.00
2022-12-31 4.56 $-0.65 0.00
2022-09-30 5.02 $0.21 23.90
2022-06-30 4.10 $0.41 10.00
2022-03-31 7.38 $0.07 105.43
2021-12-31 7.40 $0.13 56.92
2021-09-30 10.00 $-0.84 0.00
2021-06-30 12.38 $-1.26 0.00
2021-03-31 12.38 $-1.22 0.00
2020-12-31 9.79 $-1.37 0.00
2020-09-30 7.24 $-1.33 0.00
2020-06-30 8.95 $-1.33 0.00
2020-03-31 7.06 $-1.28 0.00
2019-12-31 17.15 $-1.25 0.00
2019-09-30 8.99 $-2.33 0.00
2019-06-30 9.11 $-2.36 0.00
2019-03-31 6.77 $-2.46 0.00
2018-12-31 6.02 $-2.55 0.00
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.012B $0.002B
Sol-Gel Technologies Ltd.is a clinical-stage dermatology company. It focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Its product candidates include VERED for the treatment of papulopustular rosacea, TWIN and SIRS-T for the treatment of acne vulgaris, which are in its clinical stage. Sol-Gel Technologies Ltd.is based in Israel.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.044B 6.25
Dr Reddy's Laboratories (RDY) India $11.978B 22.92
BridgeBio Pharma (BBIO) United States $4.260B 0.00
Bausch Health Cos (BHC) Canada $3.012B 2.18
Amphastar Pharmaceuticals (AMPH) United States $2.097B 12.61
Supernus Pharmaceuticals (SUPN) United States $1.962B 26.71
Taysha Gene Therapies (TSHA) United States $0.434B 30.29
Personalis (PSNL) United States $0.261B 0.00
Assembly Biosciences (ASMB) United States $0.098B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00